- Lobbying
- biomarin
Lobbying Arrangements Results for 'Biomarin'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Drug pricing; value-based arrangements. |
BioMarin
|
Horizon Government Affairs | |||
Details Rare pediatric review voucher. S 1878 and HR 1537 |
Biomarin Pharmaceutical Inc.
|
Connect 4 Strategies, LLC | |||
Details Orphan Biologics under the Orphan Drug Act; seek amendment to health-care reform legislation to enable continued rare-disease research under the Orphan Drug Act for biologics as part of follow-on b... |
BioMarin Pharmaceutical Inc.
|
Engel & Novitt, LLP | |||
Details HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) ... |
BioMarin Pharmaceutical Inc.
|
in-house lobbying | |||
Details Orphan drugs and rare diseases, matters related to drug reimbursement policy. Orphan drugs and rare disease matters |
BioMarin Pharmaceutical, Inc.
|
VENN STRATEGIES | |||
Details Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically. |
BioMarin Pharmaceutical Inc.
|
BGR Government Affairs | |||
Details Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug ... |
BioMarin Pharmaceutical Inc.
|
Chamber Hill Strategies |